Table of Content



1. Research Scope & Methodology
1.1. Study Objectives
1.2. Scope Of Study
1.3. Methodology
1.4. Assumptions & Limitations

2. Executive Summary
2.1. Market Size & Estimates
2.2. Market Overview

3. Market Dynamics
3.1. Market Definition
3.2. Key Drivers
3.2.1. Growing Prevalence Of Hypertension Across The Globe
3.2.2. Surge In Disposable Income And Healthcare Spending
3.2.3. Rising Aging Population
3.3. Key Restraints
3.3.1. Patent Expirations
3.3.2. Delay In Product Launches

4. Key Analytics
4.1. Porter’S Five Force Analysis
4.1.1. Threat Of New Entry
4.1.2. Threat Of Substitution
4.1.3. Buyer’S Power
4.1.4. Supplier’S Power
4.1.5. Competitive Rivalry
4.2. Regulatory Framework
4.3. Opportunity Matrix
4.4. Vendor Landscape
4.5. Key Investment Insights

5. Market By Drug Class
5.1. Calcium Channel Blockers
5.2. Ace Inhibitors
5.3. Beta-Adrenergic Blockers
5.4. Diuretics
5.5. Vasodilators
5.6. Other Drug Class

6. Market By End-User
6.1. Hospital Pharmacy
6.2. Retail Pharmacy
6.3. E-Commerce Websites & Online Drug Stores

7. Geographical Analysis
7.1. North America
7.1.1. The United States
7.1.2. Canada

8. Company Profiles
8.1. Allergan Plc
8.2. Aspire Bariatrics Inc
8.3. Astrazeneca Plc
8.4. Bio-Rad Laboratories Inc
8.5. Boehringer Ingelheim International Gmbh
8.6. Daiichi Sankyo Company Limited
8.7. Hill-Rom Holdings Inc
8.8. Johnson & Johnson
8.9. Lupin Limited
8.10. Medtronic Plc
8.11. Merck & Co Inc
8.12. Novartis Ag
8.13. Pfizer Inc
8.14. Sanofi
8.15. Sun Pharmaceutical Industries Ltd (Ranbaxy Laboratories)



List of Figures


List of Figures


Figure 1: Porter’S Five Force Analysis
Figure 2: Opportunity Matrix
Figure 3: Vendor Landscape
Figure 4: Key Investment Insights
Figure 5: North America Antihypertensive Drugs Market, By Drug Class, In 2019
Figure 6: North America Antihypertensive Drugs Market, By Calcium Channel Blockers, 2019-2028 (In $ Million)
Figure 7: North America Antihypertensive Drugs Market, By Ace Inhibitors, 2019-2028 (In $ Million)
Figure 8: North America Antihypertensive Drugs Market, By Beta-Adrenergic Blockers, 2019-2028 (In $ Million)
Figure 9: North America Antihypertensive Drugs Market, By Diuretics, 2019-2028 (In $ Million)
Figure 10: North America Antihypertensive Drugs Market, By Vasodilators, 2019-2028 (In $ Million)
Figure 11: North America Antihypertensive Drugs Market, By Other Drug Class, 2019-2028 (In $ Million)
Figure 12: North America Antihypertensive Drugs Market, By End-User, In 2019
Figure 13: North America Antihypertensive Drugs Market, By Hospital Pharmacy, 2019-2028 (In $ Million)
Figure 14: North America Antihypertensive Drugs Market, By Retail Pharmacy, 2019-2028 (In $ Million)
Figure 15: North America Antihypertensive Drugs Market, By E-Commerce Websites & Online Drug Stores, 2019-2028 (In $ Million)
Figure 16: North America Antihypertensive Drugs Market, Country Outlook, 2019 & 2028 (In %)
Figure 17: The United States Antihypertensive Drugs Market, 2019-2028 (In $ Million)
Figure 18: Canada Antihypertensive Drugs Market, 2019-2028 (In $ Million)


List of Tables


List of Tables


TABLE 1: MARKET SNAPSHOT - ANTIHYPERTENSIVE DRUGS
TABLE 2: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 3: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY DRUG CLASS, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 4: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 5: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY END-USER, FORECAST YEARS, 2019-2028 (IN $ MILLION)
TABLE 6: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, HISTORICAL YEARS, 2016-2019 (IN $ MILLION)
TABLE 7: NORTH AMERICA ANTIHYPERTENSIVE DRUGS MARKET, BY COUNTRY, FORECAST YEARS, 2019-2028 (IN $ MILLION)